高危住院婴儿中阿片类药物相关药物基因组变异回顾性队列研究
该回顾性队列纳入2009至2020年间在某四级儿童医院接受外显子测序的111例小于1岁高危婴儿,评估阿片类药物相关药物基因组变异频率并与Ensembl数据库比较。结果显示81.1%婴儿至少携带1个阿片相关变异纯合子,ABCB1两个位点纯合频率显著高于数据库,COMT和OPRM1位点纯合频率显著低于数据库。
要点
- 81.1%的高危住院婴儿至少为1个阿片相关PGx变异的纯合子。
- ABCB1 rs1045642和rs2032582纯合频率显著高于Ensembl数据。
- COMT rs4818和OPRM1 rs1799971纯合频率显著低于Ensembl数据。
核心结论
- 该队列中多数婴儿携带至少1个阿片相关PGx变异,且频率与广泛遗传队列显著不同。
- 结果提示PGx指导的阿片处方可能优化该人群疼痛管理并减少不良反应。
研究设计与样本
- 回顾性队列研究纳入2009至2020年某四级儿童医院小于1岁高危婴儿111例,均接受外显子测序。
- 识别COMT、DRD2/ANKK1、ABCB1、OPRM1、CYP2B6和CYP2D6的阿片反应相关变异,用卡方和Fisher精确检验与Ensembl基因组数据库比较频率。
主要发现
- 111例中62.2%为男性,47.7%为西班牙裔/拉丁裔,18.0%早产,82.0%有先天性心脏病,68.2%接受手术。
- 81.1%婴儿至少为1个阿片相关PGx变异纯合子。
- 与Ensembl数据比较,ABCB1 rs1045642纯合频率43.6% vs 18.7%(P < .001),rs2032582为42.7% vs 15.9%(P < .001)。
- COMT rs4818纯合频率2.7% vs 10.3%(P < .001),OPRM1 rs1799971为2.7% vs 7.1%(P < .001)。
- 5例手术坏死性小肠结肠炎婴儿均为至少1个阿片相关变异纯合子;最常见代谢表型为中间型(CYP2B6 35.5%,CYP2D6 20.0%)和正常型(CYP2B6 53.9%,CYP2D6 70.9%)。
关键数值与推荐
- 该队列中81.1%婴儿至少为1个阿片相关PGx变异纯合子。
- ABCB1 rs1045642纯合频率43.6%,rs2032582为42.7%,均显著高于Ensembl数据(P < .001)。
- COMT rs4818纯合频率2.7%,OPRM1 rs1799971为2.7%,均显著低于Ensembl数据(P < .001)。
- CYP2B6中间代谢型35.5%、正常型53.9%;CYP2D6中间代谢型20.0%、正常型70.9%。
临床怎么用
- 对高危住院婴儿可考虑阿片相关PGx变异检测以指导个体化阿片处方。
- 需结合更大样本及内含子PGx变异和 ancestry 可比对照验证后评估临床影响。
局限性
- 回顾性单中心队列,样本量111例。
- 未纳入内含子PGx变异,对照为Ensembl数据库而非 ancestry 可比对照。
- 需更大研究验证发现并评估临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the prevalence of opioid-related pharmacogenomic (PGx) variants in high-risk hospitalized infants and to compare these frequencies with broader genetic cohorts to assess implications for precision opioid prescribing. STUDY DESIGN: This retrospective cohort study included infants <1 year of age with high-risk conditions treated at a quaternary children's hospital between 2009 and 2020 who underwent exome sequencing. Variants associated with opioid response (COMT, DRD2/ANKK1, ABCB1, OPRM1, CYP2B6, and CYP2D6) were identified, and frequencies were compared with the Ensembl genomic database using chi-square and Fisher exact tests. RESULTS: Among 111 high-risk infants (62.2% male, 47.7% Hispanic/Latino, 18.0% born prematurely, and 82.0% with congenital heart disease), 68.2% underwent surgery. Overall, 81.1% of infants were homozygous for at least 1 opioid-related PGx variant. Compared with Ensembl data, infants in our cohort had a significantly higher frequency of homozygosity for ABCB1: rs1045642 (43.6% vs 18.7%, P < .001) and rs2032582 (42.7% vs 15.9%, P < .001) and a lower frequency of homozygosity for COMT: rs4818 (2.7% vs 10.3%, P < .001) and OPRM1: rs1799971 (2.7% vs 7.1%, P < .001). All infants with surgical necrotizing enterocolitis (n = 5) were homozygous for at least 1 opioid-related variant. The most common metabolizer phenotypes were intermediate (CYP2B6: 35.5%, CYP2D6: 20.0%) and normal (CYP2B6: 53.9%, CYP2D6: 70.9%). CONCLUSIONS: In our cohort, most infants carried at least 1 opioid-related PGx variant, with frequencies differing significantly from broader genetic cohorts. These findings highlight the potential of PGx-guided opioid prescribing to optimize pain management and reduce adverse effects in this population. Larger studies incorporating intronic PGx variants and ancestrally comparable controls are needed to validate these findings and evaluate clinical implications.
引用
- Barq RM, Ourshalimian S, Maggo S, et al. Opioid-Related Pharmacogenomic Variants in a Retrospective Cohort of High-Risk Hospitalized Infants. J Pediatr. 2025. PMID: 40683459. doi:10.1016/j.jpeds.2025.114725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。